Format

Send to

Choose Destination
Adv Anat Pathol. 2012 Jul;19(4):193-203. doi: 10.1097/PAP.0b013e31825c6bc6.

Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications.

Author information

1
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

Just over 10 years ago, germline mutations in SDHD, a gene that encodes 1 of the 4 proteins of the succinate dehydrogenase (SDH) complex, were reported in a subset of patients with hereditary paraganglioma-pheochromocytoma syndrome. Since that time, rapid discoveries have been made in this area. It is now recognized that all of the SDH genes are involved in the tumorigenesis of not only paragangliomas/pheochromocytomas, but also other tumor types, most notably gastrointestinal stromal tumors. This review will outline the genetics of SDH-deficient tumors, discuss possible mechanisms of tumorigenesis, and describe how these tumors can be identified by immunohistochemistry.

PMID:
22692282
DOI:
10.1097/PAP.0b013e31825c6bc6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center